Apixaban Intermediates

CAS No. 503615-07-4 

Molecular formula C22H22N4O4 molecular weight 406.43

EINECS No. 948-272

Chemicalbook-8 related category standards;

Reference substance - impurity reference substance;

Impurity references; Other; 

Series 1Mol file 503615-07-4.mol

apixaban (apixaban, 1), chemical name 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide, is an anticoagulant jointly developed by Bristol-Myers Squibb and Pfizer, which directly acts on coagulation factor Xa, and was approved by the European Union and FDA in May 2011 and December 2012, respectively. It was launched in April 2013 in China Chemicalbook under the trade name Alto, which is used to treat venous thrombotic diseases including deep vein thrombosis and pulmonary embolism. Apixaban is the only newer oral anticoagulant approved for secondary prevention at doses lower than the initial therapeutic dose for VTE. Clinical experts note that when considering the risks and benefits of ongoing therapy, patients and physicians may welcome anticoagulant regimens for secondary prophylaxis at lower doses, and patients are more likely to receive long-term treatment with apixaban. Studies have shown that apixaban is effective in treating VTE with fewer bleeding events than warfarin.